Search clinical trials for: B2: nab-paclitaxel

Total 6279 results

Fudan University

Recruiting

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma (INSIGHT)

Laryngeal Cancer | Laryngeal Neoplasms | Hypopharynx Cancer

China
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Breast Cancer

France, United States, Spain, United Kingdom, Australia
Erasme University Hospital
Jules Bordet Institute; University Hospital St Luc, Brussels; Belgian Group of...

Recruiting

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma (STEREOPAC)

Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Pancreatic Neoplasm

Belgium
Laekna Limited

Recruiting

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Cervical Cancer | Esophageal Cancer | NSCLC | Solid Tumor | Endometrial Cancer | Gastric and Gastroesophageal Junction Adenocarcinoma

China
Jun Guo

Not yet recruiting

A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma

China
Hebei Medical University Fourth Hospital

Recruiting

Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma (NTNC)

Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Wu Jun

Not yet recruiting

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Adenocarcinoma | Gastric Cancer | GastroEsophageal Cancer

China
Xijing Hospital

Not yet recruiting

Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer

Breast Cancer
Peking University Third Hospital

Unknown

VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer

Cervical Cancer

China
Spanish Cooperative Group for the Treatment of...

Completed

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (SEQUENCE)

Metastatic Pancreatic Adenocarcinoma

Spain
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Thuasne

Recruiting

Contribution of an Off-the-shelf Carbon Ankle Foot Orthosis (AFO) in the Management of Walking Functional Impairment (DEFISTEP)

Neuropathy (Disorder)

France
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Breast Adenocarcinoma | Inflammatory Breast Carcinoma

United States
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (ATNPA)

Locally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic Neoplasm

China
Washington University School of Medicine

Completed

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Adenocarcinoma | Pancreatic Neoplasms

United States
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
DualityBio Inc.
BioNTech SE

Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

United States, China, France, Australia
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
University of Colorado, Denver
Cancer League of Colorado

Withdrawn

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Metastatic Breast Cancer | Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | PD-L1 Gene Mutation

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal-junction Cancer

China
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Squamous Non Small Cell Lung Cancer

China, Turkey, United States, Georgia, Poland, Russian Federation, Ukraine
Shantou Central Hospital

Recruiting

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Breast Cancer

China
MedSIR

Withdrawn

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer (POLTER)

Advanced Breast Cancer
Priyanka Sharma
Novartis Pharmaceuticals

Completed

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Breast Cancer

United States
Liza Villaruz, MD

Completed

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Federation Francophone de Cancerologie Digestive

Active, not recruiting

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI (FUNGEMAX)

Metastatic Pancreatic Cancer

France, Martinique
Fudan University

Recruiting

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer (PTCA199-9)

Pancreatic Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Breast Cancer

Israel, Italy, Spain, United States, Belgium, Czechia, Australia, United Kingdom, Korea, Republic of, Romania, France, Taiwan, Latvia
Celgene

Completed

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Metastatic Breast Cancer

Ukraine
Fudan University

Active, not recruiting

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (SPARK)

Metastatic Breast Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Pancreas Cancer

United States
University of Illinois at Chicago

Recruiting

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer (BRE-10)

Breast Cancer | HER2-positive Breast Cancer

United States
BeiGene

Completed

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Non-Small Cell Lung Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

Oropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Head and Neck Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

Triple Negative Breast Neoplasms

France, Italy, Croatia, Taiwan, Australia, Argentina, Korea, Republic of, China, Israel, Russian Federation, Slovakia, Slovenia, United Kingdom, Germany, Mexico, Switzerland, Spain, Brazil, Hungary, Malaysia, South Africa, Austria, ... and more
Centre hospitalier de l'Université de Montréal...
Celgene; Jewish General Hospital; Centre de Recherche du Centre Hospitalier de... and other collaborators

Completed

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001)

Lung Cancer

Canada
Dong-A ST Co., Ltd.

Not yet recruiting

Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type 2 Diabetes

Korea, Republic of
Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
BioNTech SE

Terminated

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Gastric Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Canada
AbbVie
Idera Pharmaceuticals, Inc.

Completed

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Advanced Solid Tumors Cancer

United States, France, Germany, Israel, Netherlands, Spain

3

Subscribe